These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12895193)

  • 1. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine.
    El-Eraky H; Thomas SH
    Br J Clin Pharmacol; 2003 Aug; 56(2):198-204. PubMed ID: 12895193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater quinidine-induced QTc interval prolongation in women.
    Benton RE; Sale M; Flockhart DA; Woosley RL
    Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk.
    Vicente J; Simlund J; Johannesen L; Sundh F; Florian J; Ugander M; Wagner GS; Woosley RL; Strauss DG
    J Electrocardiol; 2015; 48(4):533-8. PubMed ID: 25796102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.
    Shin JG; Kang WK; Shon JH; Arefayene M; Yoon YR; Kim KA; Kim DI; Kim DS; Cho KH; Woosley RL; Flockhart DA
    Br J Clin Pharmacol; 2007 Feb; 63(2):206-15. PubMed ID: 17096683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure.
    Stanek EJ; Simko RJ; DeNofrio D; Pavri BB
    Pharmacotherapy; 1997; 17(3):622-5. PubMed ID: 9165569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in cardiac repolarization following intravenous sotalol administration.
    Somberg JC; Preston RA; Ranade V; Cvetanovic I; Molnar J
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):86-92. PubMed ID: 21527783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
    Bass AS; Hanson LA; Jackson TA
    J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
    Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
    J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia.
    Nagele P; Pal S; Brown F; Blood J; Miller JP; Johnston J
    Anesthesiology; 2012 Aug; 117(2):321-8. PubMed ID: 22692379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.
    Wroblewski HA; Kovacs RJ; Kingery JR; Overholser BR; Tisdale JE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4495-9. PubMed ID: 22615288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
    Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
    Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol.
    Darpo B; Karnad DR; Badilini F; Florian J; Garnett CE; Kothari S; Panicker GK; Sarapa N
    Br J Clin Pharmacol; 2014 Mar; 77(3):522-31. PubMed ID: 23819796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
    Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
    Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.